

A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours

Anne Cust

Cancer Epidemiology and Prevention Research Group
Sydney School of Public Health & Melanoma Institute Australia
The University of Sydney, Australia

SYDNEY MEDICAL SCHOOL



THE UNIVERSITY OF
SYDNEY




- › A role for genomic risk information in *cancer prevention* has not yet been established outside rare familial syndromes
 - › Highly personalised nature of providing genomic risk information may be a more powerful motivator of behaviour change than standard approaches
 - › Can genomic risk information be used as a new strategy for primary prevention and early detection of cancer in the general population?
-

Does knowledge of personal genomic risk of melanoma motivate behaviour change among the general population?

What are the broader ethical, psychological, social & economic implications?

Pilot RCT design



Eligibility: Aged 18-69 years, living in NSW

Recruitment and follow-up:

- › 41% consent, 118 randomised
 - › 92% completion of 3-month follow-up questionnaires
 - › 87% elected to have a copy of their risk information sent to their doctor
-


Estimation of genomic risk

- › 42 SNPs from 21 genes involved in pigmentation, nevus, telomere and other (unknown) pathways
 - › Risks estimated (all SNPs combined) presented as:
 - 1) an **absolute-risk** estimate of the participant's remaining lifetime risk of developing melanoma
 - 2) a **relative risk** - compared to people their age & sex
 - 2) a **risk level** – high, average, low risk
-




Distribution of relative risk estimates

Mean relative risk = 1, Median = 0.8





Objective UV measure at 3-months



Self-reported behaviours at 3-months

Compared to controls, the intervention group reported:

- Reduced intentional tanning ($p=0.06$)
 - More likely to limit time in the sun during midday hours ($p=0.06$)
 - Increased shade-seeking behaviour ($p=0.13$)
 - Increased confidence identifying melanoma ($p=0.008$)
 - Effect sizes appeared stronger for the average-risk group (and $p<0.05$ for all measures above)
-

Psychological measures at 3-months

Compared to controls, the intervention group reported:

- **No difference in skin-cancer related worry**
 - Overall mean difference: -0.1, 95% CI -0.3, 0.1 (on a scale of 1-5)
 - High-risk group: 0.1 , 95% CI -0.2, 0.5

 - **No difference in psychological distress and well-being (MHI-5)**
 - Overall mean difference: -0.4, 95% CI -4.7, 4.0 (on a scale of 0-100)
 - High-risk group: -0.1, 95% CI -8.3, 8.2
-

- ...genuinely surprised by the result ...and as a result of the risk info his wife has now booked him into the GP next week to have his first skin check
 - Participant [with very fair skin, lots of moles and 3 x BCCs] could understand why she would receive a high risk result. She said her high risk result reinforces her need to be vigilant about sun protection and screening
 - Participant felt it was very valuable to receive this information so he was aware he was at higher risk and could undergo appropriate checks
-

- “I appreciated that you sent the info about my genetic risk of melanoma to my GP. That prompted a conversation and a whole body skin check :) we're going to schedule that in biannually with my pap smear from now on.”
 - “I have just renegotiated my life insurance and I ticked the box around have you had any genetic tests as "No" I did not want to cause reason for them requesting my medical records unduly, and did not want my premiums affected.”
-

- › Results from this pilot study demonstrate the strong interest, feasibility and acceptability of giving information on personalised genomic risk of melanoma to the public.
 - › These preliminary results suggested some beneficial changes to preventive behaviours
 - › There was no evidence of adverse impacts on general distress or worry
-

Collaborators

- Amelia Smit, Ainsley Newson, David Espinoza, Georgina Fenton, Lucinda Freeman, Louise Keogh, Phyllis Butow, Graham Mann, Michael Kimlin, Matthew Law, Rachael Morton, Judy Kirk, Suzanne Dobbinson, Peter Kanetsky, Kate Dunlop.

Funding

- Career Development Fellowships from the NHMRC and Cancer Institute NSW
 - Sydney Catalyst Translational Cancer Centre pilot & seed grant
 - University of Sydney Cancer SPARC grant
-